Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Share-based Compensation (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Share-based Compensation for 6 consecutive years, with $721000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 44.49% to $721000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, up 26.58% year-over-year, with the annual reading at $2.2 million for FY2025, 26.58% up from the prior year.
  • Share-based Compensation hit $721000.0 in Q4 2025 for Insight Molecular Diagnostics, up from $521000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q3 2022 to a low of $386000.0 in Q2 2024.
  • Historically, Share-based Compensation has averaged $1.2 million across 5 years, with a median of $777500.0 in 2023.
  • Biggest five-year swings in Share-based Compensation: soared 73.1% in 2021 and later plummeted 81.52% in 2023.
  • Year by year, Share-based Compensation stood at $1.7 million in 2021, then surged by 53.61% to $2.6 million in 2022, then tumbled by 81.52% to $484000.0 in 2023, then increased by 3.1% to $499000.0 in 2024, then skyrocketed by 44.49% to $721000.0 in 2025.
  • Business Quant data shows Share-based Compensation for IMDX at $721000.0 in Q4 2025, $521000.0 in Q3 2025, and $504000.0 in Q2 2025.